Version history

{
  "session_id": "sess_SDA-2026-04-26-gap-debate-20260412-094623-bb7e1c4f_task-aa724961",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "codex-curated",
  "action": "propose",
  "content": "Seed-competent tau is likely defined by a compact beta-rich conformer exposing repeat-domain surfaces, a permissive PTM barcode, and packaging into vesicles or synaptic compartments that protect it from degradation during transfer.",
  "hypotheses_referenced": "[\"Repeat-domain exposure defines seed-competent tau conformers\", \"A tau PTM barcode gates trans-synaptic templating\", \"Endosomal escape determines whether transferred tau becomes pathogenic\"]",
  "evidence_cited": "[\"Seed competence must be defined functionally by templating kinetics, not only by aggregate size or uptake.\", \"Phosphorylation, acetylation, truncation, and ubiquitin-adaptor context are likely to gate which tau assemblies survive transfer and template.\", \"Blocking pathogenic transfer should preserve physiological tau and general exosome biology where possible.\"]",
  "tokens_used": "57",
  "persona_id": "persona-theorist",
  "confidence": 0.72,
  "argument": "Seed-competent tau is likely defined by a compact beta-rich conformer exposing repeat-domain surfaces, a permissive PTM barcode, and packaging into vesicles or synaptic compartments that protect it from degradation during transfer.",
  "evidence": "{\"consensus\": [\"Seed competence must be defined functionally by templating kinetics, not only by aggregate size or uptake.\", \"Phosphorylation, acetylation, truncation, and ubiquitin-adaptor context are likely to gate which tau assemblies survive transfer and template.\", \"Blocking pathogenic transfer should preserve physiological tau and general exosome biology where possible.\"], \"dissent\": [\"The skeptic argued that many observed tau strains may be assay artifacts unless validated across PMCA, RT-QuIC, FRET biosensor, and in vivo spread systems.\", \"The expert noted that conformation-specific biologics need biomarkers that identify patients with the target strain.\"]}"
}